<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>OCTAGAM IMMUNE GLOBULIN (HUMAN)- human immunoglobulin g solution </strong><br>Octapharma Pharmazeutika Produktionsgesellschaft m.b.H.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
Octagam, Immune Globulin Intravenous (Human) 5% Liquid Preparation Initial U.S. Approval: 2004 - These highlights do not include all the information needed to use Octagam, Immune Globulin Intravenous (Human), safely and effectively. See full prescribing information for Octagam.</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="HighlightsHanging"><span class="Exdent">•</span>Octagam is an immune globulin intravenous (human), 5% liquid, indicated for treatment of primary humoral <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> (PI) (1).  (<a href="#section-1">1</a>)</p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="HighlightsHanging"><span class="Exdent">•</span>Intravenous use only (2).  (<a href="#section-2">2</a>)</p>
<p class="HighlightsHanging"><span class="Exdent">•</span>  (<a href="#section-2">2</a>)</p>
<table class="Bullet">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left">Indication</th>
<th class="Botrule Lrule Rrule Toprule" align="left">Dose</th>
<th class="Botrule Lrule Rrule Toprule" align="left">Initial Infusion rate</th>
<th class="Botrule Lrule Rrule Toprule" align="left">Maintenance infusion rate (if tolerated)</th>
</tr></thead>
<tbody><tr class="First Last">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="Highlighta">PI  (<a href="#section-2">2</a>)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="Highlighta">300-600mg/kg  (<a href="#section-2">2</a>)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="Highlighta">0.5mg/kg/min   (<a href="#section-2">2</a>)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="Highlighta">3.33 mg/kg/min  (<a href="#section-2">2</a>)</p>
<p class="Highlighta">Every 3-4 weeks  (<a href="#section-2">2</a>)</p>
</td>
</tr></tbody>
</table>
<p class="HighlightsHanging"><span class="Exdent">•</span>Ensure that patients with pre-existing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> are not volume depleted; discontinue Octagam 5% liquid if renal function deteriorates (2.4).  (<a href="#section-2">2</a>)</p>
<p class="HighlightsHanging"><span class="Exdent">•</span>For patients at risk of renal dysfunction or thrombotic events, administer Octagam 5% liquid at the minimum infusion rate practicable (2.4).  (<a href="#section-2">2</a>)</p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="HighlightsHanging"><span class="Exdent">•</span>Octagam 5% liquid is supplied in 1.0 g, 2.5 g, 5 g , 10 g or 25 g single use bottles (3, 16)  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<p class="HighlightsHanging"><span class="Exdent">•</span>Anaphylactic or severe systemic reactions to human immunoglobulin (4)  (<a href="#section-4">4</a>)</p>
<p class="HighlightsHanging"><span class="Exdent">•</span>IgA deficient patients with antibodies against IgA and a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (4)  (<a href="#section-4">4</a>)</p>
<p class="HighlightsHanging"><span class="Exdent">•</span>Patients with acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to corn (4)  (<a href="#section-4">4</a>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<p class="HighlightsHanging"><span class="Exdent">•</span>IgA deficient patients with antibodies against IgA are at greater risk of developing severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> Epinephrine should be available immediately to treat any acute severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. (5.1)  (<a href="#section-5">5</a>)</p>
<p class="HighlightsHanging"><span class="Exdent">•</span>Monitor renal function, including blood urea nitrogen and serum creatinine, and urine output in patients at risk of developing <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. (5.2)  (<a href="#section-5">5</a>)</p>
<p class="HighlightsHanging"><span class="Exdent">•</span>Falsely elevated blood glucose readings may occur during and after the infusion of Octagam 5% liquid with some glucometer and test strip systems (5.3)  (<a href="#section-5">5</a>)</p>
<p class="HighlightsHanging"><span class="Exdent">•</span><span class="product-label-link" type="condition" conceptid="4284608" conceptname="Hyperproteinemia">Hyperproteinemia</span>, increased serum viscosity and <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> occur in patients receiving IGIV therapy. (5.4)  (<a href="#section-5">5</a>)</p>
<p class="HighlightsHanging"><span class="Exdent">•</span>Thrombotic events have occurred in patients receiving IGIV therapy. Monitor patients with known risk factors for thrombotic events; consider baseline assessment of blood viscosity for those at risk of hyperviscosity. (5.5)  (<a href="#section-5">5</a>)</p>
<p class="HighlightsHanging"><span class="Exdent">•</span><span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic Meningitis</span> Syndrome has been reported with Octagam 5% liquid and other IGIV treatments, especially with high doses or rapid infusion. (5.6)  (<a href="#section-5">5</a>)</p>
<p class="HighlightsHanging"><span class="Exdent">•</span><span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span> can develop subsequent to IGIV therapy due to enhanced RBC sequestration (5.7)  (<a href="#section-5">5</a>)</p>
<p class="HighlightsHanging"><span class="Exdent">•</span>IGIV recipients should be monitored for pulmonary adverse reactions (<span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>) (5.8)  (<a href="#section-5">5</a>)</p>
<p class="HighlightsHanging"><span class="Exdent">•</span>The product is made from human plasma and may contain infectious agents, e.g. viruses and, theoretically, the Creutzfeldt-Jakob disease agent (5.9)  (<a href="#section-5">5</a>)</p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="HighlightsHanging"><span class="Exdent">•</span>Most common adverse reactions with an incidence of &gt; 5% during a clinical trial were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. (6.1). To report SUSPECTED ADVERSE REACTIONS, contact Octapharma at 1-866-766-4860 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  (<a href="#section-6">6</a>)</p></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<p class="HighlightsHanging"><span class="Exdent">•</span>The passive transfer of antibodies may confound the results of serological testing (7).  (<a href="#section-7">7</a>)</p>
<p class="HighlightsHanging"><span class="Exdent">•</span>The passive transfer of antibodies may interfere with the response to live viral vaccines (7).  (<a href="#section-7">7</a>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<p class="HighlightsHanging"><span class="Exdent">•</span>Pregnancy: no human or animal data. Use only if clearly needed (8.1).  (<a href="#section-8">8</a>)</p>
<p class="HighlightsHanging"><span class="Exdent">•</span>In patients over age 65 or in any person at risk of developing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, do not exceed the recommended dose, and infuse Octagam 5% liquid at the minimum infusion rate practicable (8.5).  (<a href="#section-8">8</a>)</p>
<p class="HighlightsHanging"><span class="Exdent">•</span>  (<a href="#section-8">8</a>)</p>
<p class="HighlightsHanging"><span class="Exdent">•</span>See 17 for PATIENT COUNSELING INFORMATION.  (<a href="#section-8">8</a>)</p>
<p class="HighlightsHanging"><span class="Exdent">•</span>  (<a href="#section-8">8</a>)</p>
<p class="HighlightsHanging"><span class="Exdent">•</span>Revised: September 2009  (<a href="#section-8">8</a>)</p>
<p class="HighlightsHanging"><span class="Exdent">•</span>  (<a href="#section-8">8</a>)</p>
<p class="HighlightsHanging"><span class="Exdent">•</span>  (<a href="#section-8">8</a>)</p>
<p class="HighlightsHanging"><span class="Exdent">•</span>  (<a href="#section-8">8</a>)</p>
<p class="HighlightsHanging"><span class="Exdent">•</span>_______________________________________________________________________________________________________________________________________  (<a href="#section-8">8</a>)</p>
<p class="HighlightsHanging"><span class="Exdent">•</span>  (<a href="#section-8">8</a>)</p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 12/2009</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">Primary Humoral <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Diseases (PI)</a></h2>
<h1><a href="#section-2" class="toc">DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">Preparation and handling</a></h2>
<h2><a href="#section-2.2" class="toc">Treatment of Primary Humoral <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span></a></h2>
<h2><a href="#section-2.3" class="toc">Missed Doses</a></h2>
<h2><a href="#section-2.4" class="toc">Administration</a></h2>
<h1><a href="#section-3" class="toc">DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">Sensitivity</a></h2>
<h2><a href="#section-5.2" class="toc"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span></a></h2>
<h2><a href="#section-5.3" class="toc">Blood Glucose Monitoring</a></h2>
<h2><a href="#section-5.4" class="toc"><span class="product-label-link" type="condition" conceptid="4284608" conceptname="Hyperproteinemia">Hyperproteinemia</span></a></h2>
<h2><a href="#section-5.5" class="toc">Thrombotic events</a></h2>
<h2><a href="#section-5.6" class="toc"><span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic meningitis</span> syndrome</a></h2>
<h2><a href="#section-5.7" class="toc"><span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span></a></h2>
<h2><a href="#section-5.8" class="toc">Transfusion-Related Acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">Lung Injury</span> (<span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>)</a></h2>
<h2><a href="#section-5.9" class="toc">General</a></h2>
<h2><a href="#section-5.10" class="toc">Laboratory Tests</a></h2>
<h1><a href="#section-6" class="toc">ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">Adverse Drug Reaction Overview</a></h2>
<h2><a href="#section-6.2" class="toc">Clinical Trials Experience</a></h2>
<h2><a href="#section-6.3" class="toc">Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">DESCRIPTION</a></h1>
<h2><a href="#section-10.1" class="toc">Composition</a></h2>
<h1><a href="#section-11" class="toc">CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">NON-CLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">Information for Patients</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="INDICATIONS-AND-USAGE"></a><a name="section-1"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="PRIMARY-HUMORAL-<span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">IMMUNODEFICIENCY</span>-DISEASES--PI-"></a><a name="section-1.1"></a><p></p>
<h2>Primary Humoral <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Diseases (PI)</h2>
<p class="First">
Octagam is an immune globulin intravenous (human) 5% liquid indicated for treatment of primary humoral <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> (PI), such as congenital agammaglobulinemia, common variable <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span>, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome and severe combined immunodeficiencies.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DOSAGE-AND-ADMINISTRATION"></a><a name="section-2"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">
For intravenously use only</p>
<div class="Section" data-sectionCode="42229-5">
<a name="PREPARATION-AND-HANDLING"></a><a name="section-2.1"></a><p></p>
<h2>Preparation and handling</h2>
<ul class="Disc">
<li>
Octagam 5% liquid should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if turbid and/or discoloration is observed.</li>
<li>
Octagam 5% liquid must not be mixed with other medicinal products or administered simultaneously with other intravenous preparation in the same infusion set. Do not mix with immune globulin intravenous (IGIV) products from other manufacturers.</li>
<li>
Do not freeze. Solutions that have been frozen should not be used.</li>
<li>
Octagam 5% liquid bottle is for single use only. Octagam 5% liquid contains no preservative. Any bottle that has been entered should be used promptly. Partially used bottles should be discarded.</li>
<li>
Content of Octagam 5% liquid bottles may be pooled under aseptic conditions into sterile infusion bags and infused within 8 hours after pooling. </li>
<li>
Do not use after expiration date.</li>
<li>
Octagam 5% liquid should not be diluted.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="TREATMENT-OF-PRIMARY-HUMORAL-<span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">IMMUNODEFICIENCY</span>"></a><a name="section-2.2"></a><p></p>
<h2>Treatment of Primary Humoral <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span></h2>
<p class="First">
As there are significant differences in the half-life of IgG among patients with primary humoral immunodeficiencies, the frequency and amount of immunoglobulin therapy may vary from patient to patient. The proper amount can be determined by monitoring clinical response.</p>
<p>
The dose of Octagam 5% liquid for replacement therapy in primary humoral <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> diseases is 300 to 600 mg/kg body weight (6-12ml/kg) administered every 3 to 4 weeks. The dosage may be adjusted over time to achieve the desired trough levels and clinical responses.</p>
<p>
If a patient is at risk of <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span> exposure (ie., outbreak in US or travel to endemic areas outside of the US) and receives a dose of less than 400 mg/kg every 3 to 4 weeks, the dose should be increased to at least 400 mg/kg. If a patient has been exposed to <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, this dose should be administered as soon as possible after exposure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="MISSED-DOSES"></a><a name="section-2.3"></a><p></p>
<h2>Missed Doses</h2>
<p class="First">
If a patient on regular treatment missed a dose, the missed dose should be administered as soon as possible, and then treatment should continue as before.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ADMINISTRATION"></a><a name="section-2.4"></a><p></p>
<h2>Administration</h2>
<p class="First">
Octagam 5% liquid should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if turbid and/or discoloration is observed.</p>
<p>
Octagam 5% liquid should be at room temperature during administration. Only administer intravenously.</p>
<p>
Any bottle that has been opened should be used promptly. Partially used bottles should be discarded.</p>
<p>
Octagam 5% liquid is not supplied with an infusion set. If an in-line filter is used the pore size should be 0.2 – 200 microns.</p>
<p>
Do not use a needle of larger than 16 gauge to prevent the possibility of coring. Insert needle only once, within the stopper area delineated (by the raised ring for penetration). The stopper should be penetrated perpendicular to the plane of the stopper within the ring.</p>
<p><span class="Underline">
Rate of Administration</span></p>
<p>
It is recommended that Octagam 5% liquid be initially infused at infusion rates stated below, at least until the physician has had adequate experience with a given patient.</p>
<p>
Infusion rates: 0.5mg/kg/min (30mg/kg/hr for the first 30 minutes; if tolerated, advance to 1mg/kg/min (60mg/kg/hr) for the second 30 minutes; and if further tolerated, advance to 2mg/kg/min (120mg/kg/hr) for the third 30 minutes. Thereafter the infusion can be maintained at a rate up to, but not exceeding, 3.33mg/kg/min (200mg/kg/hr)</p>
<p>
For patients judged to be at risk for developing renal dysfunction, administer Octagam 5% liquid at the minimum infusion rate practicable, not to exceed 0.07 ml/kg (3.3 mg/kg)/minute (200 mg/kg/hour).</p>
<br><p><span class="Bold">
Table 1</span></p>
<table>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left">
Rate of Administration</th>
<th class="Botrule Lrule Rrule Toprule" align="center">
mg/kg/min  (mg/kg/hour)</th>
<th class="Botrule Lrule Rrule Toprule" align="center">
ml/kg/min</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
first 30 min</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
0.5   (30)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
0.01</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
next 30 min</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
1.0   (60)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
0.02</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
next 30 min</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
2.0   (120)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
0.04</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
Maximum</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
&lt; 3.33   (&lt;200)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
&lt;0.07</p></td>
</tr>
</tbody>
</table>
<br><br><br><br><br><br><br><br><br><p>
Certain severe adverse drug reactions may be related to the rate of infusion. Slowing or stopping the infusion usually allows the symptoms to disappear promptly.</p>
<p>
Ensure that patients with pre-existing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> are not volume depleted; discontinue Octagam 5% liquid if renal function deteriorates.</p>
<p>
For patients at risk of renal dysfunction or <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>, administer Octagam 5% liquid at the minimum infusion rate practicable.</p>
<p><span class="Bold">
Incompatibilities</span></p>
<p>
Octagam 5% liquid must not be mixed with other medicinal products or administered simultaneously with other intravenous preparations in the same infusion set.</p>
<p><span class="Bold">
Shelf-life</span></p>
<p>
Octagam 5% liquid may be stored for 24 months at +2°C to + 25°C (36°F to 77°F) from the date of manufacture.</p>
<p><a name="OLE_LINK1"></a><span class="Bold">
Special Precautions for Storage</span></p>
<p>
Do not freeze. Frozen product should not be used.</p>
<p>
Do not use after expiration date.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="DOSAGE-FORMS-AND-STRENGTHS"></a><a name="section-3"></a><p></p>
<h1>DOSAGE FORMS AND STRENGTHS</h1>
<p class="First"><span class="Italics">
Octagam 5% liquid is supplied in 1.0 g, 2.5 g, 5 g , 10 g or 25 g single use bottles (See How Supplied/Storage and Handling [16]).</span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CONTRAINDICATIONS"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">
Octagam 5% liquid is contraindicated in patients who have acute severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to human immunoglobulin.</p>
<p><span class="Italics">
Octagam 5% liquid contains trace amounts of IgA (not more than 0.2 mg/ml in a 5% solution). It is contraindicated in IgA deficient patients with antibodies against IgA and history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (See Description [11]).</span></p>
<p>
Octagam 5% liquid is contraindicated in patients with acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to corn. Octagam 5% liquid contains maltose, a disaccharide sugar which is derived from corn. Patients known to have corn allergies should avoid using Octagam 5% liquid.</p>
<br>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="WARNINGS-AND-PRECAUTIONS"></a><a name="section-5"></a><p></p>
<h1>WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="SENSITIVITY"></a><a name="section-5.1"></a><p></p>
<h2>Sensitivity</h2>
<p class="First">
Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> may occur [<a href="#REFERENCES">
1</a>
] (See Contraindications [4.1]). In case of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, Octagam 5% liquid infusion should be immediately discontinued and appropriate treatment instituted. Epinephrine should be immediately available for treatment of acute severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>. IgA deficient patients with antibodies against IgA are at greater risk of developing severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> when administered Octagam 5% liquid (See Contraindications [4.2]). Patients known to have corn allergies should avoid using Octagam 5% liquid (See Contraindications [4.3]).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="RENAL-FAILURE"></a><a name="section-5.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span></h2>
<p class="First">
Assure that patients are not volume depleted prior to the initiation of the infusion of Octagam 5% liquid.</p>
<p><span class="Italics">
Periodic monitoring of renal function tests and urine output is particularly important in patients judged to have a potential increased risk of developing <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. Renal function, including a measurement of blood urea nitrogen (BUN)/serum creatinine, should be assessed prior to the initial infusion of Octagam 5% liquid and again at appropriate intervals thereafter. If renal function deteriorates, discontinuation of the product should be considered (See Patient Counselling Information [17])</span></p>
<p><span class="Italics">
For patients judged to be at risk for developing renal dysfunction and/or at risk of developing thrombotic events, it may be prudent to reduce the amount of product infused per unit time by infusing Octagam 5% liquid at a maximum rate less than 0.07 ml/kg (3.3 mg/kg)/minute (200 mg/kg/hour) (See Boxed Warning, and Dosage and Administration [2.4]).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="BLOOD-GLUCOSE-MONITORING"></a><a name="section-5.3"></a><p></p>
<h2>Blood Glucose Monitoring</h2>
<p class="First">
Blood Glucose Testing [<a href="#REFERENCES">
2</a>
] :some types of blood glucose testing systems (for example, those based on the glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) or glucose-dye-oxidoreductase methods) falsely interpret the maltose contained in Octagam 5% liquid as glucose. This has resulted in falsely elevated glucose readings and, consequently, in the inappropriate administration of insulin, resulting in life-threatening <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Also, cases of true <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may go untreated if the hypoglycemic state is masked by falsely elevated glucose readings. Accordingly, when administering Octagam 5% liquid, the measurement of blood glucose must be done with a glucose-specific method. The product information of the blood glucose testing system, including that of the test strips, should be carefully reviewed to determine if the system is appropriate for use with maltose-containing parenteral products. If any uncertainty exists, contact the manufacturer of the testing system to determine if the system is appropriate for use with maltose-containing parenteral products.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="<span class="product-label-link" type="condition" conceptid="4284608" conceptname="Hyperproteinemia">HYPERPROTEINEMIA</span>"></a><a name="section-5.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4284608" conceptname="Hyperproteinemia">Hyperproteinemia</span></h2>
<p class="First">
<span class="product-label-link" type="condition" conceptid="4284608" conceptname="Hyperproteinemia">Hyperproteinemia</span>, increased serum viscosity and <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> may occur in patients receiving IGIV therapy. The <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> is likely to be a pseudohyponatremia as demonstrated by a decreased calculated serum <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> or elevated osmolar gap. Distinguishing true <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> from pseudohyponatremia is clinically critical, as treatment aimed at decreasing serum free water in patients with pseudohyponatremia may lead to <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>, a further increase in serum viscosity and a disposition to <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> [<a href="#REFERENCES">
3</a>
].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="THROMBOTIC-EVENTS"></a><a name="section-5.5"></a><p></p>
<h2>Thrombotic events</h2>
<p class="First">
Thrombotic events have been reported in association with IGIV therapy [<a href="#REFERENCES">
4</a>
],[<a href="#REFERENCES">
5</a>
],[<a href="#REFERENCES">
6</a>
]. Patients at risk may include those with a history of <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>, multiple cardiovascular risk factors, advanced age, impaired <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorders</span>, <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> of immobilization and/or known or suspected hyperviscosity. The potential risks and benefits of IGIV should be weighed against those of alternative therapies for all patients for whom IGIV administration is being considered. Baseline assessment of blood viscosity should be considered in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia / markedly high triacylglycerols (triglycerides), or monoclonal gammopathies.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ASEPTIC-<span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">MENINGITIS</span>-SYNDROME"></a><a name="section-5.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic meningitis</span> syndrome</h2>
<p class="First">
<span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic meningitis</span> syndrome (AMS) has been reported to occur infrequently in association with IGIV treatment. Discontinuation of IGIV treatment has resulted in remission of AMS within several days without sequelae. The syndrome usually begins within several hours to two days following IGIV treatment and rapid infusion. It is characterized by symptoms and signs including severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4228784" conceptname="Nuchal rigidity">nuchal rigidity</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, painful eye movements, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Cerebrospinal fluid (CSF) studies are frequently positive with <span class="product-label-link" type="condition" conceptid="4240184" conceptname="Pleocytosis">pleocytosis</span> up to several thousand cells per cu mm, predominantly from the granulocytic series, and elevated protein levels up to several hundred mg/dl. Patients exhibiting such symptoms and signs should receive a thorough neurological examination, including CSF studies, to rule out other causes of <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>. It appears that patients with a history of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> may be more susceptible. [<a href="#REFERENCES">
7</a>
] (See Patient Counselling Information [17]).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="<span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">HEMOLYSIS</span>"></a><a name="section-5.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span></h2>
<p class="First">
IGIV products can contain blood group antibodies which may act as hemolysins and induce in vivo coating of red blood cells with immunoglobulin, causing a positive direct antiglobulin reaction and, rarely, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> [<a href="#REFERENCES">
8</a>
]. <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span> can develop subsequent to IGIV therapy due to enhanced RBC sequestration [See ADVERSE REACTIONS] [<a href="#REFERENCES">
9</a>
]. IGIV recipients should be monitored for clinical signs and symptoms of <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>. If signs and/or symptoms of <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> are present after IGIV infusion, appropriate confirmatory laboratory testing should be done (See Patient Counseling Information [17]).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="TRANSFUSION-RELATED-ACUTE-LUNG-INJURY--<span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>-"></a><a name="section-5.8"></a><p></p>
<h2>Transfusion-Related Acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">Lung Injury</span> (<span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>)</h2>
<p class="First">
There have been reports of noncardiogenic <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> [Transfusion-Related Acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">Lung Injury</span> (<span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>)] in patients administered IGIV [<a href="#REFERENCES">
10</a>
]. <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span> is characterized by severe <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>, normal left ventricular function, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and typically occurs within 1-6 hours after transfusion. Patients with <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span> may be managed using oxygen therapy with adequate ventilatory support.</p>
<p><span class="Italics">
IGIV recipients should be monitored for pulmonary adverse reactions (See Patient Counseling Information [17]). If <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span> is suspected, appropriate tests should be performed for the presence of anti-neutrophil antibodies in both the product and patient serum. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GENERAL"></a><a name="section-5.9"></a><p></p>
<h2>General</h2>
<p class="First"><span class="Italics">
Because this product is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. All <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Octapharma. The physician should discuss the risks and benefits of this product with the patient, before prescribing or administering it to the patient (See Patient Counseling Information [17]).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LABORATORY-TESTS"></a><a name="section-5.10"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">
If signs and/or symptoms of <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> are present after IGIV infusion, appropriate confirmatory laboratory testing should be done.</p>
<p>
If <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span> is susppected, appropriate tests should be performed for the presence of anti-neutrophil antibodies in both the product and patient serum.</p>
<p>
Because of the potentially increased risk of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, baseline assessment of blood viscosity should be considered in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies.</p>
<br>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ADVERSE-REACTIONS"></a><a name="section-6"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ADVERSE-DRUG-REACTION-OVERVIEW"></a><a name="section-6.1"></a><p></p>
<h2>Adverse Drug Reaction Overview</h2>
<p class="First">
The most serious adverse reactions observed with Octagam 5% Liquid treatment have been immediate <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>, and <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>.</p>
<p>
The most common adverse reactions observed with Octagam 5% Liquid treatment during clinical trial (&gt; 5%) were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="CLINICAL-TRIALS-EXPERIENCE"></a><a name="section-6.2"></a><p></p>
<h2>Clinical Trials Experience</h2>
<p class="First"><span class="Italics">
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a product cannot be directly compared to rates in the clinical trials of another product and may not reflect the rates observed in clinical practice.</span></p>
<p>
The clinical trial database includes a multi-center, open-label, single arm study in 46 children and adults with PI. Subjects participated in the study for a mean of 346 days and received 300 to 450 mg/kg every 21 days or 400 to 600 mg/kg every 28 days. Infusions were initiated at a rate of 30 mg/kg/hour for the first 30 minutes, and, if tolerated, could be advanced to a maximum tolerated rate not exceeding 200 mg/kg/hour. Over half of the subjects were male (n=28; 61%), and more than half were on the 28-day infusion schedule (n=27; 59%). The mean age of subjects was 31.5 years.</p>
<br><p>
Six subjects experienced a total of 12 SAEs (<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (2 occurrences), <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, <span class="product-label-link" type="condition" conceptid="436027" conceptname="Coxsackie virus disease">coxsackie viral infection</span>, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal calculus</span> (2 occurrences), blood culture positive, <span class="product-label-link" type="condition" conceptid="4171926" conceptname="Ketonuria">ketonuria</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, and <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> pseudomembranosus). Eleven of the 12 SAEs were not suspected to be related to study drug; the other SAE was noted before the subject began receiving the next scheduled infusion, and it was not temporally related to the previous infusion.</p>
<p>
Pre-medications were used in 165 (25.2%) out of 654 infusions and in 14 (30.4%) out of 46 patients. Infusions were slowed or interrupted in 9 out of 489 infusions (1.84%) without pre-medication and in 10 out of 165 infusions (6.06%) with pre-medication. Five out of 32 (15.63%) patients who never received any pre-medication had at least one slowed or interrupted infusion, whereas 9 out of 14 (64.29%) patients who received pre-medication at least once also had a slowed or interrupted infusion.</p>
<br><p>
Six of the 46 subjects in the trial (13%) were withdrawn from the study: 2 on the subjects' request; 1 because of investigator's decision (non-compliance); 1 because of loss to follow-up; 1 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (<span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, not suspected to be related to study drug); and 1 by error of the study coordinator.</p>
<p>
All adverse events in trial OCTA-06, irrespective of the causality assessment, reported by at least 5% of subjects during the 12-months treatment are given in the table below.</p>
<br><p><span class="Italics"><span class="Bold">
Table 2: Subjects and Infusions with at least one Adverse Event Irrespective of Causality (Study OCTA-06)</span></span></p>
<br><table>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left"></th>
<th class="Botrule Lrule Toprule" align="right">
Octagam </th>
<th class="Botrule Rrule Toprule" align="left">
5% liquid</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First"></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
No. of subjects (%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
No. of infusions (%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="right"><p class="First">
 Total</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
46 (100%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
654 (100%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal congestion</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
24 (52%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
39 (6%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> NOS</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
23 (50%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
45 (7%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> NOS</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
22 (48%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
62 (9%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
20 (43%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
46 (7%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">Sore throat</span> NOS</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
16 (35%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
25 (4%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
15 (33%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
19 (3%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> NOS</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
12 (26%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
15 (2%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhoea</span> NOS</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
11 (24%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
22 (3%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span> NOS</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
10 (22%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
14 (2%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
9 (20%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
11 (2%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
9 (20%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
15 (2%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
8 (17%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
14 (2%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">Rhinorrhoea</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
8 (17%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
9 (1%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span> NOS</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
8 (17%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
13 (2%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
7 (15%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
9 (1%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
7 (15%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
8 (1%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in limb</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
7 (15%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
10 (2%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4220211" conceptname="Congestion of nasal sinus">Sinus congestion</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
7 (15%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
9 (1%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
5 (11%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
10 (2%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reaction</span> NOS</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
5 (11%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
11 (2%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">Wheezing</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
5 (11%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
8 (1%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> NOS</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
4 (9%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
5 (0.8%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma aggravated</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
4 (9%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
10 (2%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> NEC</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
4 (9%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
4 (0.6%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span> NEC</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
4 (9%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
4 (0.6%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
4 (9%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
5 (0.8%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">Earache</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
4 (9%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
6 (0.9%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
4 (9%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
7 (1%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal infection</span> NOS</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
4 (9%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
4 (0.6%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">Injection site pain</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
4 (9%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
4 (0.6%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> NEC</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
4 (9%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
4 (0.6%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="260123" conceptname="Acute sinusitis">Sinusitis acute</span> NOS</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
4 (9%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
 8 (1%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span> NOS</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
4 (9%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
8 (1%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">Vaginal candidiasis</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
4 (9%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
7 (1%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> NOS</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
3 (7%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
3 (0.5%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> (exc <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>)</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
3 (7%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
4 (0.6%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnoea</span> NOS</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
3 (7%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
3 (0.5%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
3 (7%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
5 (0.8%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4080696" conceptname="Discharge from eye">Eye discharge</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
3 (7%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
3 (0.5%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">Eye irritation</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
3 (7%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
3 (0.5%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> NOS</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
3 (7%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
5 (0.8%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis media</span> NOS</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
3 (7%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
4 (0.6%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> NOS</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
3 (7%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
4 (0.6%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="257683" conceptname="Posterior rhinorrhea">Postnasal drip</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
3 (7%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
3 (0.5%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">Productive cough</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
3 (7%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
3 (0.5%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Rigors</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
3 (7%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
4 (0.6%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">Throat irritation</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
3 (7%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
3 (0.5%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span> NOS</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">
3 (7%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">
8 (1%)</p></td>
</tr>
</tbody>
</table>
<p>
The adverse reactions in trial OCTA-06 reported by at least 5% of subjects during the 12-month treatment are given in the table below.</p>
<br><p><span class="Bold">
Table 3: Subjects and Infusions with At Least One Adverse Reaction (Study OCTA-06)</span></p>
<br><table>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left"></th>
<th class="Botrule Lrule Toprule" align="right">
Octagam</th>
<th class="Botrule Rrule Toprule" align="left">
5% liquid</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First"></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
No. of subjects (%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
No. of infusions (%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
Total</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
46 (100%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
654 (100%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> NOS</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
7 (15%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
 18 (3%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
3 (7%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
 4 (0.6%)</p></td>
</tr>
</tbody>
</table>
<p>
The following table provides an overview on the temporally associated adverse events (TAAEs) during and within different time-points after the end of Octagam infusion.</p>
<br><p><span class="Italics"><span class="Bold">
Table 4: Overview on TAAEs Occurring During and Over a Specified Number of Hours after the End of Infusion, Irrespective of Causality (Study OCTA-06)</span></span></p>
<br><table>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left">
Total # of infusions (N=654)</th>
<th class="Botrule Lrule Toprule" align="right">
Time-Points</th>
<th class="Botrule Toprule" align="left"></th>
<th class="Botrule Rrule Toprule" align="left"></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
24 hrs</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
48hrs</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
72hrs</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
Total # of TAAEs</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
172</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
183</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
189</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
Proportion of infusions with TAAEs</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
26.3%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
28.0%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
28.9%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
Upper bound 1 sided 97.5% CI for proportion of TAAEs</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
29.7%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
31.4%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
32.4%</p></td>
</tr>
</tbody>
</table>
<p>
All temporally associated adverse events (TAAEs) in trial OCTA-06, irrespective of the causality assessment, reported by at least 5% of subjects within 72 hours after the end of the infusion are given in the table below.</p>
<br><p><span class="Italics"><span class="Bold">
Table 5: TAAEs During and Over 72 Hours After End of Infusion, Irrespective of Causality (Study OCTA-06)</span></span></p>
<br><table>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left">
TAAE</th>
<th class="Botrule Lrule Rrule Toprule" align="left">
Subjects (%)n=46</th>
<th class="Botrule Lrule Rrule Toprule" align="left">
Infusion (%)N=654</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> NOS</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
15 (32.6%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
28 (4.3%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> NOS</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
12 (26.1%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
13 (2.0%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal congestion</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
10 (21.7%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
11 (1.7%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
7 (15.2%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
10 (1.5%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
7 (15.2%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
7 (1.1%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reaction</span> NOS</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
5 (10.9%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
11 (1.7%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">Sore throat</span> NOS</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
5 (10.9%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
5 (0.8%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> NOS</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
5 (10.9%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
5 (0.8%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
4 (8.7%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
6 (0.9%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhoea</span> NOS</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
4 (8.7%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
5 (0.8%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
4 (8.7%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
5 (0.8%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">Injection site pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
4 (8.7%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
4 (0.6%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
4 (8.7%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
5 (0.8%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span> NOS</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
4 (8.7%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
5 (0.8%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">Wheezing</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
4 (8.7%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
6 (0.9%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma aggravated</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
3 (6.5%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
4 (0.6%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">Eye irritation</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
3 (6.5%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
3 (0.5%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal infection</span> NOS</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
3 (6.5%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
3 (0.5%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in limb</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
3 (6.5%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
5 (0.8%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">Rhinorrhoea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
3 (6.5%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
3 (0.5%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
<span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span> NOS</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
3 (6.5%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
3 (0.5%)</p></td>
</tr>
</tbody>
</table>
<p>
The subset of drug related temporally associated adverse events (TAAEs) in trial OCTA-06 reported by at least 5% of subjects within 72 hours after the end of the infusion is given in the table below.</p>
<br><p><span class="Italics"><span class="Bold">
Table 6: Drug-Related TAAEs During and Over 72 Hours After End of Infusion (Study OCTA-06)</span></span></p>
<br><table>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left">
TAAE</th>
<th class="Botrule Lrule Rrule Toprule" align="left">
Subjects (%)n=46</th>
<th class="Botrule Lrule Rrule Toprule" align="left">
Infusion (%)N=654</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
 <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> NOS</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
 6 (13.0%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
 15 (2.3%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
 <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
 3 (6.5%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
 4 (0.6%)</p></td>
</tr>
</tbody>
</table>
<p><span class="Underline">
Laboratory Abnormalities </span></p>
<p>
Standard clinical laboratory evaluations were performed Study OCTA-06. Three subjects (7%) had incidences of AST (&gt;2.5 x ULN) which were all assessed as clinically non-significant. Four subjects (9%) had incidences of serum creatinine increases being stable throughout the course of the study. Therefore, these observations were not regarded as indicative of acute renal dysfunction.</p>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="POSTMARKETING-EXPERIENCE"></a><a name="section-6.3"></a><p></p>
<h2>Postmarketing Experience</h2>
<p class="First"><span class="Italics">
Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure.</span></p>
<p><span class="Bold">
Octagam 5% liquid Postmarketing Experience</span></p>
<p>
The following adverse reactions have been identified during post-approval use of Octagam 5% liquid. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to Octagam 5% liquid.</p>
<br><table>
<thead><tr class="First Last"><th class="Botrule Lrule Rrule Toprule" align="left">
Blood and lymphatic system disordersLeukopenia, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">haemolytic anaemia</span></th></tr></thead>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">
<span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span> </p>
<p>
<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic oedema</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">oedema</span></p>
</td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">
Metabolic and nutritional disorders</p>
<p>
<span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">Fluid overload</span></p>
</td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">
Psychiatric disorders</p>
<p>
<span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span></p>
</td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">
<span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></p>
<p>
<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">meningitis aseptic</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paraesthesia</span></p>
</td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">
<span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span></p>
<p>
<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span></p>
</td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">
<span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></p>
<p>
<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">peripheral circulatory failure</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span></p>
</td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">
Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></p>
<p>
<span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">Respiratory failure</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary oedema</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnoea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></p>
</td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">
<span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></p>
<p>
<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhoea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></p>
</td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">
Skin and subcutaneous tissue disorders</p>
<p>
<span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Eczema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span></p>
</td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">
Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></p>
<p>
<span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span></p>
</td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">
Renal and urinary disorders</p>
<p>
<span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Renal failure acute</span></p>
</td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">
General disorders and administration site conditions</p>
<p>
<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flush</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span></p>
</td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">
Investigations</p>
<p>
Hepatic enzymes increased, blood glucose false positive</p>
</td></tr>
</tbody>
</table>
<p><span class="Bold">
General</span></p>
<p>
The following adverse reactions have been identified during post-approval use of IGIV products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to IGIV products:</p>
<br><table>
<thead><tr class="First Last"><th class="Botrule Lrule Rrule Toprule" align="left">
RespiratoryApnea, <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">Acute Respiratory Distress Syndrome</span> (<span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span>), <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">Transfusion Related Acute Lung Injury</span> (<span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>), <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span></th></tr></thead>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">
Cardiovascular</p>
<p>
<span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">vascular collapse</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span></p>
</td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">
Neurological</p>
<p>
<span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">Coma</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></p>
</td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">
Integumentary</p>
<p>
Steven-Johnson syndrome, <span class="product-label-link" type="condition" conceptid="4309632" conceptname="Epidermolysis">epidermolysis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="137944" conceptname="Bullous dermatosis">bullous dermatitis</span></p>
</td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">
Hematologic</p>
<p>
<span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">Pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>, positive direct antiglobulin (Coombs) test</p>
</td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">
General / Body as a Whole</p>
<p>
<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span></p>
</td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">
Musculoskeletal</p>
<p>
<span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></p>
</td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">
Gastrointestinal</p>
<p>
Hepatic dysfunction, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></p>
</td></tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="DRUG-INTERACTIONS"></a><a name="section-7"></a><p></p>
<h1>DRUG INTERACTIONS</h1>
<p class="First">
Admixtures of Octagam 5% liquid with other drugs and intravenous solutions have not been evaluated. It is recommended that Octagam 5% liquid be administered separately from other drugs or medications which the patient may be receiving. The product should not be mixed with IGIVs from other manufacturers.</p>
<p>
The infusion line may be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> before and after administration of Octagam 5% liquid with either normal saline or 5% dextrose in water.</p>
<p>
Various passively transferred antibodies in immunoglobulin preparations can confound the results of serological testing.</p>
<p><span class="Italics">
Antibodies in Octagam 5% liquid may interfere with the response to live viral vaccines, such as <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, <span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">mumps</span>, and <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span>. Physicians should be informed of recent therapy with IGIVs, so that administration of live viral vaccines, if indicated, can be appropriately delayed 3 or more months from the time of IGIV administration.</span></p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="USE-IN-SPECIFIC-POPULATIONS"></a><a name="section-8"></a><p></p>
<h1>USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="PREGNANCY"></a><a name="section-8.1"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">
Pregnancy Category C. Animal reproduction studies have not been conducted with Octagam 5% liquid. It is also not known whether Octagam 5% liquid can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Octagam 5% liquid should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="NURSING-MOTHERS"></a><a name="section-8.2"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">
Octagam 5% liquid has not been evaluated in nursing mothers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="PEDIATRIC-USE"></a><a name="section-8.3"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">
Octagam 5% liquid was evaluated in 11 pediatric subjects (age range 6 – 16 years). There were no obvious differences observed between adults and pediatric subjects with respect to pharmacokinetics, efficacy and safety. No pediatric specific dose requirements were necessary to achieve the desired serum IgG levels.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GERIATRIC-USE"></a><a name="section-8.4"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First"><span class="Italics">
Patients &gt; 65 years of age may be at increased risk for developing certain adverse reactions such as <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> (See Boxed Warnings and Precautions [5.3]). In the clinical trial only 4 geriatric patients ( &gt; 65 years) were enrolled, a number insufficient to determine whether geriatric patients respond differently from younger subjects. In these 4 patients no particular issues were observed.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="OVERDOSAGE"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">
<span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> may lead to <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">fluid overload</span> and hyperviscosity, particularly in the elderly and in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="DESCRIPTION"></a><a name="section-10"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">
Immune Globulin Intravenous (Human), Octagam 5% liquid, is a solvent/detergent (S/D)-treated, sterile preparation of highly purified <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">immunoglobulin G</span> (IgG) derived from large pools of human plasma. Octagam 5% liquid is a solution for infusion which must be administered intravenously.</p>
<p>
All units of human plasma used in the manufacture of Octagam 5% liquid are provided by FDA-approved blood establishments only, and are tested by FDA-licensed serological tests for HBsAg, antibodies to HCV and HIV and Nucleic Acid Test (NAT) for HCV and HIV-1 and found to be non-reactive (negative).</p>
<p><span class="Italics">
The product is manufactured by the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> ethanol fractionation process followed by ultrafiltration and chromatography. The manufacturing process includes treatment with an organic S/D mixture composed of tri-n-butyl phosphate (TNBP) and Triton X-100 (Octoxynol). The Octagam 5% liquid manufacturing process provides a significant viral reduction in in vitro studies (table 7). These reductions are achieved through a combination of process steps including <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> ethanol fractionation, S/D treatment and pH 4 treatment.</span></p>
<p><span class="Bold">
Table 7: In vitro reduction factor during Octagam 5% liquid manufacturing </span></p>
<br><div class="Figure"><img alt="Image File" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=810c8752-a7cb-0bce-777d-8539429773c2&amp;name=img0001.jpg"></div>
<br><br><p>
WNV: West Nile Virus</p>
<p>
HIV-1: Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus - 1</p>
<p>
PRV: Pseudorabies Virus</p>
<p>
SBV: Sindbis Virus</p>
<p>
MEV: Mouse <span class="product-label-link" type="condition" conceptid="373189" conceptname="Encephalomyelitis">Encephalomyelitis</span> Virus</p>
<p>
PPV: Porcine Parvovirus</p>
<br><div class="Section" data-sectionCode="42229-5">
<a name="COMPOSITION"></a><a name="section-10.1"></a><p></p>
<h2>Composition</h2>
<p class="First">
The composition of Octagam 5% liquid is shown in table 8 as follows:</p>
<br><p><span class="Bold">
Table 8 : Composition</span></p>
<br><table>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left">
Component</th>
<th class="Botrule Lrule Rrule Toprule" align="center">
Quantity/ml</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
Protein, of which not less than 96% is human normal <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">immunoglobulin G</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
50 mg</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
Maltose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
100 mg</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
Triton X-100</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
not more than 5 mcg</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
TNBP</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
not more than 1 mcg</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
IgA</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
not more than 0.2 mg</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
IgM</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
not more than 0.1 mg</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
Water for Injection</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
ad.</p></td>
</tr>
</tbody>
</table>
<p>
This preparation contains approximately 50 mg of protein per ml (5%) of which not less than 96% is human normal <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">immunoglobulin G</span>. Octagam 5% liquid contains not more than 3% aggregates, not less than 90% monomers and dimers and not more than 3% fragments.</p>
<p>
The sodium content of the final solution is not more than 30 mmol/l and the pH is between 5.1 and 6.0. The <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> is 310 - 380 mosmol/kg.</p>
<p>
The manufacturing process for Octagam 5% liquid isolates IgG without additional chemical or enzymatic modification, and the Fc portion is maintained intact Octagam 5% liquid contains the IgG antibody activities present in the donor population. IgG subclasses are fully represented with the following approximate percents of total IgG: IgG<span class="Sub">
1</span>
 is 65%, IgG<span class="Sub">
2</span>
 is 30%, IgG<span class="Sub">
3</span>
 is 3% and IgG<span class="Sub">
4</span>
 is 2%.</p>
<p>
Octagam 5% liquid contains a broad spectrum of IgG antibodies against bacterial and viral agents that are capable of opsonization and neutralization of microbes and toxins.</p>
<p>
Octagam 5% liquid contains no preservative and no sucrose.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CLINICAL-PHARMACOLOGY"></a><a name="section-11"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="MECHANISM-OF-ACTION"></a><a name="section-11.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">
Octagam 5% liquid supplies a broad spectrum of opsonic and neutralizing IgG antibodies against bacteria or their toxins. The mechanism of action in PI has not been fully elucidated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="PHARMACODYNAMICS"></a><a name="section-11.2"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">
Octagam 5% liquid contains mainly <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">immunoglobulin G</span> (IgG) with a broad spectrum of antibodies against various infectious agents reflecting the IgG activity found in the donor population. Octagam 5% liquid which is prepared from pooled material from not less than 1000 donors, has an IgG subclass distribution similar to that of native human plasma. Adequate doses of IGIV can restore abnormally low IgG level to the normal range. Standard pharmacodynamic studies were not performed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="PHARMACOKINETICS"></a><a name="section-11.3"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">
Peak levels of IgG are reached immediately after infusion of Octagam 5% liquid. It has been shown that after infusion, exogenous IgG is distributed relatively rapidly between plasma and extravascular fluid until approximately half is partitioned in the extravascular space. Therefore a rapid initial drop in serum IgG is expected [<a href="#REFERENCES">
11</a>
].</p>
<p>
Studies show that the apparent half-life of Octagam 5% liquid is approximately 40 days in immunodeficient patients.</p>
<p>
The main pharmacokinetic parameters of Octagam 5% liquid measured as total IgG in study OCTA-06 are displayed below:</p>
<p>
In the pharmacokinetic study, a subset of 14 patients aged between 10 and 70 years with PI underwent pharmacokinetic assessments. Patients received infusions of Octagam 5% liquid (300 to 600 mg/kg) every 3 (n=6) to 4 (n=8) weeks for 12 months. Pharmacokinetic samples were collected at baseline and after the 5<span class="Sup">
th</span>
 month of treatment. After the infusion, blood samples were taken until day 28 (for patients on a 21 day schedule, the interval was extended to 4 weeks for the pharmacokinetic study).</p>
<br><p><span class="Bold">
Table 9: PK Parameters of Octagam 5% liquid (Study OCTA-06) </span></p>
<br><table>
<thead><tr class="First Last">
<th class="Botrule Lrule Toprule" align="left"></th>
<th class="Botrule Toprule" align="center"></th>
<th class="Botrule Toprule" align="center"></th>
<th class="Botrule Toprule" align="right">
Octagam</th>
<th class="Botrule Rrule Toprule" align="left">
5% liquid</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First"></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
N</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
Mean</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
SD</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
Median</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
Cmax (mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
14</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
16.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
3.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
16.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
AUC (mg*h/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
14</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
7022</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
1179</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
7103</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
T1/2 (days)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
14</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
40.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
17.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
36.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">
Trough IgG Level</p>
<p>
21 Day Infusion Schedule (mg/dL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
19</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
881.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
151.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
859</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">
Trough IgG Level</p>
<p>
28 Day Infusion Schedule (mg/dL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
25</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
763.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
156.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
760</p></td>
</tr>
</tbody>
</table>
<p>
The half-life of IgG can vary considerably from person to person. In particular, high concentrations of lgG and <span class="product-label-link" type="condition" conceptid="4242214" conceptname="Hypermetabolism">hypermetabolism</span> associated with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> have been seen to coincide with a shortened half-life of IgG. Longer half-lives are often seen with immunodeficient patients [<a href="#REFERENCES">
12</a>
].</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="NON-CLINICAL-TOXICOLOGY"></a><a name="section-12"></a><p></p>
<h1>NON-CLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="CARCINOGENESIS--MUTAGENESIS--IMPAIRMENT-OF-FERTILITY"></a><a name="section-12.1"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">
No studies were conducted on carcinogenesis, mutagenesis, or impairment of fertililty with Octagam 5% liquid.</p>
<p>
Repeated-dose toxicity studies and the genotoxic studies gave no evidence of carcinogenic properties of TNBP and Octoxynol [<a href="#REFERENCES">
13</a>
], [<a href="#REFERENCES">
14</a>
].</p>
<p><span class="Italics">
The results of in vitro and in vivo genotoxicity studies for TNBP and Octoxynol were negative. The results of studies on the embryotoxic and teratogenic properties of TNBP and Octoxynol in rats and rabbits at a wide range of i.v. doses were also negative.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ANIMAL-TOXICOLOGY-AND-OR-PHARMACOLOGY"></a><a name="section-12.2"></a><p></p>
<h2>Animal Toxicology and/or Pharmacology</h2>
<p class="First">
No studies were conducted on non-clinical pharmacology, toxicology, local tolerance or pharmacokinetics with Octagam 5% liquid.</p>
<p>
A variety of single-dose toxicity studies were performed for TNBP and Octoxynol alone or in combination. The lowest toxic dose of TNBP + Octoxynol (1+5) was 10,000 mcg/kg BM in rats after intravenous administration. Studies on 13-week toxicity were performed for combinations of TNBP + Octoxynol in a broad dose range intravenously in dogs and rats. In these studies the lowest toxic dose for rats was local 60mcg TNBP/kg +300mcg Octoxynol/kg BM i.v. (concentration: 0.0006% and 0.003%, respectively) and systemic 300mcg TNBP/kg + 1,500mcg Octoxynol/kg BM i.v. (concentration: 0.003% and 0.015%, respectively). The lowest toxic dose for dogs was local 50 mcg TNBP/kg + 250mcg Octoxynol/kg BM i.v. (concentration: 0.005% and 0.025%, respectively) and systemic 500mcg TNBP/kg + 2,500mcg Octoxynol/kg BM i.v. (concentration: 0.05% and 0.25%, respectively).</p>
<p>
Local tolerance of TNBP and Octoxynol was evaluated from the experiments on repeat-dose toxicity (rats, dogs) and on developmental toxicity (rats, rabbits). In these animal studies the lowest dose exerting local adverse reactions was 50 + 250 mcg/kg BM (TNBP + Octoxynol; daily injections) in dogs. At this dose 4 out of 6 dogs were affected starting in week 7 of treatment.</p>
<p>
A pharmacokinetic study was carried out in rats given 300 mcg of TNBP/kg and 1,500 mcg Octoxynol/kg BM i.v. The plasma half-life for TNBP was approximately 20 minutes. Octoxynol was not detected.</p>
<br>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="CLINICAL-STUDIES"></a><a name="section-13"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">
In an open-label, multicenter study, 46 patients (including 10 patients between the ages of 6 and 12, and one 15 years old) with primary humoral <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> (PI) received Octagam 5% liquid individualized doses of 300 - 600 mg/kg every 3 or 4 weeks for 12 months. Six patients discontinued the study prematurely.</p>
<p>
Eligible patients had to meet the following key inclusion criteria: aged 3 years or older; had a PI that had as a significant component <span class="product-label-link" type="condition" conceptid="440072" conceptname="Hypogammaglobulinemia">hypogammaglobulinemia</span> or antibody deficiency; had been receiving IGIV replacement therapy at a steady dose for at least 3 months prior to study entry and had maintained a trough level of at least 320 mg/dL above baseline serum IgG levels.</p>
<p>
Patients were excluded if they had a history of severe reactions to blood or any blood-derived product; if they had a selective <span class="product-label-link" type="condition" conceptid="433171" conceptname="Selective immunoglobulin A deficiency">IgA deficiency</span> or demonstrable antibodies to IgA; if they received blood or any blood product or derivative other than a commercially available IGIV within 3 months prior to study entry; if they had hepatic function abnormalities or a positive direct Coombs test at screening; if they had a pre-existing <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, a history of drug or <span class="product-label-link" type="condition" conceptid="433753" conceptname="Alcohol abuse">alcohol abuse</span> in the previous 12 months or acquired medical condition known to cause secondary immune deficiency; if they were receiving long-term daily treatment with steroids at a dose of at least 1 mg/kg/day; if they had a requirement for pre-medication for IGIV infusion other than aspirin, acetaminophen, or other non-steroidal anti-inflammatory drug, or antihistamine; and if the received immunosuppressive or immunomodulatory drugs.</p>
<p>
The primary efficacy endpoint was the number of episodes of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>/patient/year. Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> included <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> or <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="141663" conceptname="Osteomyelitis">osteomyelitis</span>/<span class="product-label-link" type="condition" conceptid="80482" conceptname="Suppurative arthritis">septic arthritis</span>, visceral <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span> or bacterial or <span class="product-label-link" type="condition" conceptid="433403" conceptname="Viral meningitis">viral meningitis</span>. Secondary efficacy variables were: the number of days of work/school missed; the number and days of hospitalizations; the number of visits to physicians for acute problems and/or visits to hospital emergency rooms; and the number of other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> documented by radiograph and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.</p>
<p>
For the primary endpoint, which was the number of episodes of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, the observed rate was 0.1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> per patient per year (5 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> over 43.5 patient-years).</p>
<p><span class="Bold">
Table 10: Summary of Secondary Efficacy Variables</span></p>
<br><table>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left">
Variable </th>
<th class="Botrule Lrule Rrule Toprule" align="center">
Subjects N</th>
<th class="Botrule Lrule Rrule Toprule" align="center">
Subjects %</th>
<th class="Botrule Lrule Rrule Toprule" align="center">
Total Days or Visits</th>
<th class="Botrule Lrule Rrule Toprule" align="center">
Total Subject Years</th>
<th class="Botrule Lrule Rrule Toprule" align="center">
Days or Visits/Subj./YearEstimate</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
Work/School Days Missed</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
30</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
65</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
241</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
43.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
5.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
Days in Hospital</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
16</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
43.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
0.4</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
Visits to Physician/ER</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
27</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
59</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
92</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
43.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">
2.1</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="REFERENCES"></a><a name="section-14"></a><p></p>
<h1>REFERENCES</h1>
<ol class="Arabic">
<li>
Duhem, C., Dicato, M. A. and Ries, F. Side-effects of intravenous immune globulins. Clin. Exp. Immunol. 97 Suppl 1, 79-83 (1994).</li>
<li>
Kannan, S., Rowland, C. H., Hockings, G. I. and Tauchmann, P. M. Intragam can interfere with blood glucose monitoring. Med. J. Aust. 180, 251-252 (2004).</li>
<li>
Steinberger, B. A., Ford, S. M., Coleman, T. A. Intravenous Immunoglobulin Therapy Results in Post-infusional <span class="product-label-link" type="condition" conceptid="4284608" conceptname="Hyperproteinemia">Hyperproteinemia</span>, Increased Serum Viscosity, and Pseudohyponatremia. Am J Hematol 73:97-100 (2003)</li>
<li>
Dalakas, M. C. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>. Neurology 44, 223-226 (1994).</li>
<li>
Wolberg, A. S., Kon, R. H., Monroe, D. M. and Hoffman, M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am. J Hematol. 65, 30-34 (2000).</li>
<li>
Go RS, Call TG: Deep <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc75:83-85 (2000)</li>
<li>
Sekul, E. A., Cupler, E. J. and Dalakas, M. C. <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic meningitis</span> associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern. Med. 121, 259-262 (1994).</li>
<li>
Pierce LR, Jain N: Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 17:241-251 (2003)</li>
<li>
Kessary-Shoham H., Levy, Y., Shoenfeld, Y., Lorber, M. and Gershon, H. In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration. Journal of Autoimmunity. 13, 129-135 (1999).</li>
<li>
Rizk, A., Gorson, K. C., Kenney, L. and Weinstein, R. Transfusion-related acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">lung injury</span> after the infusion of IVIG. Transfusion 41, 264-268 (2001).</li>
<li>
Koleba T, Ensom MH: Pharmacokinetics of intravenous immunoglobulin: a systematic review. Pharmacotherapy 26:813-827 (2006)</li>
<li>
Lever, A. M., Yap, P. L., Cuthbertson, B., Wootton, R. and Webster, A. D. Increased half-life of gammaglobulin after prolonged intravenous replacement therapy. Clin Exp. Immunol 67, 441-446 (1987).</li>
<li>
Auletta, CS., Kotkoskie, LA., Saulog, T., Richter, WR. A dietary oncogenicity study of tributyl phosphate in the CD-1 mouse. Toxicology 128, 135-141 (1998a).</li>
<li>
Auletta CS., Weiner ML., Richter WR. A dietary toxicity/oncogenicity study of tributyl phosphate in the rat. Toxicology 128: 125-134 (1998b).</li>
</ol>
<p class="First">
Octagam 5% liquid is supplied in 1.0 g, 2.5 g, 5 g, 10 g or 25 g single use bottles.</p>
<br><table>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left">
NDC Number </th>
<th class="Botrule Lrule Rrule Toprule" align="left">
NDC Number</th>
<th class="Botrule Lrule Rrule Toprule" align="right">
Size</th>
<th class="Botrule Lrule Rrule Toprule" align="right">
Grams Protein</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
Octapharma Pharmazeutika Produktionsges.m.b.H</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
Octapharma AB</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First"></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First"></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
67467 – 843 - 01</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
68209 – 843 - 01</p></td>
<td class="Botrule Lrule Rrule Toprule" align="right"><p class="First">
20 ml</p></td>
<td class="Botrule Lrule Rrule Toprule" align="right"><p class="First">
1.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
67467 – 843 – 02</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
68209 – 843 – 02</p></td>
<td class="Botrule Lrule Rrule Toprule" align="right"><p class="First">
50 ml</p></td>
<td class="Botrule Lrule Rrule Toprule" align="right"><p class="First">
2.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
67467 – 843 – 03</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
68209 – 843 – 03</p></td>
<td class="Botrule Lrule Rrule Toprule" align="right"><p class="First">
100 ml</p></td>
<td class="Botrule Lrule Rrule Toprule" align="right"><p class="First">
5.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
67467 – 843 – 04</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
68209 – 843 – 04</p></td>
<td class="Botrule Lrule Rrule Toprule" align="right"><p class="First">
200 ml</p></td>
<td class="Botrule Lrule Rrule Toprule" align="right"><p class="First">
10.0</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">
67467 – 843 – 05</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First"></p></td>
<td class="Botrule Lrule Rrule Toprule" align="right"><p class="First">
500 ml</p></td>
<td class="Botrule Lrule Rrule Toprule" align="right"><p class="First">
25.0</p></td>
</tr>
</tbody>
</table>
<p>
Octagam 5% liquid is not supplied with an infusion set. If a filtered infusion set is used (not mandatory), the filter size must be 0.2 – 200 microns.</p>
<p>
Components used in the packaging of Octagam 5% liquid are latex-free.</p>
<p>
Octagam 5% liquid may be stored for 24 months at +2°C to + 25°C (36°F to 77°F) from the date of manufacture.</p>
<p>
Do not use after expiration date.</p>
<p>
Do not freeze. Frozen product should not be used.</p>
<p>
Any unused product or waste material should be disposed of in accordance with local requirements.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="PATIENT-COUNSELING-INFORMATION"></a><a name="section-15"></a><p></p>
<h1>PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="INFORMATION-FOR-PATIENTS"></a><a name="section-15.1"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">
Inform patients of the early signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, generalised <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, tightness of the chest, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>. If allergic symptoms occur, patients should contact their physicians immediately.</p>
<br><p>
Inform patients to also immediately report the following to their physician:</p>
<p>
• signs and symptoms of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failures</span>, such as decreased urine output, sudden <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>/<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and/or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></p>
<p>
• signs and symptoms of <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>, such as <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">neck stiffness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, sensitivity to light, painful eye movements, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p>
• signs and symptoms of <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>, such as <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, increased heart rate, yellowing of the skin or eyes, and dark-colored urine</p>
<p>
• signs and symptoms of <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>, such as severe <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>, normal left ventricular function, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span> typically occurs within 1 to 6 hours following transfusion</p>
<br><p>
Inform patients that Octagam 5% liquid is made from human plasma and may contain infectious agents that can cause disease (e.g., viruses, and, theoretically, the CJD agent). Inform patients that the risk Octagam 5% liquid may transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing the donated plasma for certain virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and by inactivating and/or removing certain viruses during manufacturing.</p>
<br><p>
Inform patients that administration of IgG may interfere with the response to live viral vaccines such as <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, <span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">mumps</span> and <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span>. Inform patients to notify their immunizing physician of therapy with Octagam 5% liquid.</p>
<br><p>
Octapharma USA Inc.Hoboken, NJ 07030</p>
<br>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="PACKAGE-LABEL---PRINCIPAL-DISPLAY-PANEL"></a><a name="section-16"></a><p></p>
<h1></h1>
<br><p class="First">
PACKAGE LABEL – PRINCIPAL DISPLAY PANEL</p>
<br><p>
Immune Globulin Intravenous (Human), 5%</p>
<br><p><span class="Bold">
Octapharma Pharmazeutika Produktionsges.m.b.H</span></p>
<p><span class="Bold">
20 mL </span></p>
<p>
NDC 67467-843-01</p>
<br><div class="Figure"><img alt="Image File" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=810c8752-a7cb-0bce-777d-8539429773c2&amp;name=img0002.jpg"></div>
<br><br><p><span class="Bold">
100mL</span></p>
<p>
NDC 67467-843-03</p>
<br><div class="Figure"><img alt="Image File" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=810c8752-a7cb-0bce-777d-8539429773c2&amp;name=img0003.jpg"></div>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OCTAGAM IMMUNE GLOBULIN (HUMAN) 		
					</strong><br><span class="contentTableReg">immune globulin solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67467-843</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">Intravenous</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HUMAN <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">IMMUNOGLOBULIN G</span></strong> (HUMAN <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">IMMUNOGLOBULIN G</span>) </td>
<td class="formItem">HUMAN <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">IMMUNOGLOBULIN G</span></td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67467-843-05</td>
<td class="formItem">500 mL in 1 BOTTLE, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:67467-843-04</td>
<td class="formItem">200 mL in 1 BOTTLE, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:67467-843-03</td>
<td class="formItem">100 mL in 1 BOTTLE, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:67467-843-02</td>
<td class="formItem">50 mL in 1 BOTTLE, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:67467-843-01</td>
<td class="formItem">20 mL in 1 BOTTLE, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125062</td>
<td class="formItem">05/21/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Octapharma Pharmazeutika Produktionsgesellschaft m.b.H.
							(301119178)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0fe33130-c3e4-4baa-db1f-4ce138e6c2e5</div>
<div>Set id: 810c8752-a7cb-0bce-777d-8539429773c2</div>
<div>Version: 4</div>
<div>Effective Time: 20090909</div>
</div>
</div> <div class="DistributorName">Octapharma Pharmazeutika Produktionsgesellschaft m.b.H.</div></p>
</body></html>
